Diagnosis and risk
MDS is diagnosed when persistent cytopenias are accompanied by dysplastic marrow features. IPSS-R and molecular findings estimate prognosis and guide treatment intensity.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Treatment options
Lower-risk disease may be managed with observation, growth factors, transfusion and lenalidomide in selected del(5q) cases. Higher-risk disease may receive hypomethylating agents and be considered for allogeneic transplant.
- Observation and transfusion support
- Growth factors and lenalidomide in selected patients
- Hypomethylating agents for higher-risk disease
- Allogeneic transplant assessment
- Iron overload monitoring
Access
Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital. Bring all blood count and marrow reports.